看好创新药投资方向，市场观望情绪浓厚

Group 1 - The core viewpoint indicates that there is a strong focus on upcoming domestic and overseas meetings, particularly the Federal Reserve's interest rate decision, leading to a cautious market sentiment and reduced trading volume [1] - The domestic real estate sector is weakening, and the recovery is slightly below expectations, suggesting that proactive policies are likely to be implemented [1] - The Federal Reserve's direction towards interest rate cuts remains unchanged, which is expected to positively influence market conditions [1] Group 2 - The investment strategy includes a high proportion of high-quality combinations at 25% and low-quality combinations at 30%, indicating a balanced approach to risk and return [1] - There is a positive outlook on the innovative pharmaceutical investment sector, with adjustments made to include the "Jia Shi Zhong Zheng Hong Guo Tong Innovation Drug ETF" in the portfolio [1][3] - Current market indicators show a valuation temperature of 47.39°, a fear and greed index of 38, and a stock-bond value ratio temperature of 44°, suggesting that the stock market valuation is moderate [1]